A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation

A Novel Strategy Combined Regional Anticoagulation in Membrane Oxygenator and Low-intensity of Systemic Anticoagulation Applied in Management of Extracorporeal Membrane Oxygenation

ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.

Inclusion Criteria:

• age older than 18 years old
• received ECMO because of severe respiratory failure

Exclusion Criteria:

• anticoagulant contraindications
• cerebral infarction or suspected patients
• severe hypertension
• women in gestational and lactational period
• hemophilia
• allergic to heparin or Nafamostat
• unwilling or unable to complete the study